REPL שווי מלא של הפעילות העסקית Replimune Group, Inc.

Replimune Group, Inc. (REPL) develops Immulytic oncolytic viruses while awaiting the results of final-stage melanoma trials. Progress is accelerating through AI modeling and automation, although physicians remain indispensable. The lack of stable revenue leaves the company dependent on external capital. This chart of the current share price on GURU.Markets, standing at 1091.56, confirms a stage of active R&D investment in the absence of mature products.

Replimune Group, Inc. (REPL) utilizes outsourcing in clinical trials to minimize capital expenditures, making the historical enterprise value chart a key tool for assessing resource management efficiency. This metric determines the actual acquisition price of the business by summing market capitalization and net debt, allowing investors to distinguish the company's organic growth from balance sheet expansion driven by borrowed funds.